Elotuzumab for the treatment of multiple myeloma

Future Oncol. 2014 May;10(6):949-56. doi: 10.2217/fon.14.56.

Abstract

New agents are awaited for the treatment of multiple myeloma and research is ongoing for the development of monoclonal antibodies (MoAbs) targeting the tumor cells. One of the most promising MoAb is elotuzumab, the only humanized IgG1 MoAb specifically targeting CS1 (SLAMF7), a cell surface glycoprotein that is highly expressed in plasma cells. Preclinical and clinical data on elotuzumab will be presented in this article.

Keywords: CS1; elotuzumab; lenalidomide; monoclonal antibody; multiple myeloma.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Drug Evaluation, Preclinical
  • Humans
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / genetics
  • Multiple Myeloma / metabolism
  • Receptors, Immunologic / genetics
  • Receptors, Immunologic / metabolism
  • Signaling Lymphocytic Activation Molecule Family
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Receptors, Immunologic
  • SLAMF7 protein, human
  • Signaling Lymphocytic Activation Molecule Family
  • elotuzumab